Alexion Pharmaceuticals
Alexion became the rare disease division of AstraZeneca after being acquired by the company in 2021.1)
COVID-19
The company had been running clinical trials on ULTOMIRIS (ravulizumab-cwvz) in hospitalized COVID-19 patients until they were paused in January 2021 due to lack of efficacy.2)
Payments from Alexion
The following is a developing list of individuals and organizations that Alexion has given money to related to the COVID-19 pandemic:
| Name | Type | Amount | Description |
|---|---|---|---|
| Ronald McDonald House Charities | Grant | $200,000.00 | Alexion awarded RMHC a Rare Belonging® grant in 2020.3) |
External links
1)
Kemp, A. (2021, July 21). Acquisition of Alexion completed. AstraZeneca. https://archive.ph/c5apv
2)
Goulart, M. (2021, January 13). Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized
Patients with Severe COVID-19. Alexion Pharmaceuticals, Inc. https://archive.ph/u2NbV
3)
Corporate Sponsors of RMHC. Ronald McDonald House Charities. Retrieved January 17, 2022, from https://archive.ph/UEpBP